To more precisely identify the location of complement dysregulation in the tauopathy cases, immunofluorescence was performed on CBD, GGT, and PiD cases with double labeling for complement (the activation trigger C1q and activation products C3b/iC3b and TCC) and either tau (AT8) or myelin (PLPc). This evidence concerns the gene MAPT and tauopathy.